Date: 2015-09-17
Type of information: Opening of new premises
Compound: BioInject (biopharmaceutical manufacturing facility in Austria)
Company: Sandoz (Switzerland)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On September 17 2015, Sandoz, the generics and biosimilars business of Novartis, officially opened its new cutting-edge biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria. It is the result of over 150 million euro worth of investment with creation of 100 highly skilled jobs. BioInject is a state-of-the-art facility that will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics. This new facility now means that 18,000 syringes can be filled per hour and 100 packaged per minute. It will play an important role in driving the next wave of biosimilars and novel biologics growth at Sandoz and Novartis Pharmaceuticals - growth that will ultimately help address unmet medical needs and broaden patient access to key biologics products. BioInject will become a central part of Novartis’ biomanufacturing network which also includes facilities in Slovenia, Singapore and France.Total investment of 2.2 billion euro in Austria since 1996 More than 2.2 billion euro has been invested in Austria since Novartis was first established in 1996. The group currently has over 4,600 employees at four sites and is therefore an important economic contributor particularly in the provinces of Tyrol, Upper Austria and Vienna. Sandoz recently became the first company to introduce a biosimilar in the United States, Zarxio®.
Financial terms:
Latest news:
